CENDRIX
Research Library
Regulatory and Responsible Research·Regulatory Science·5 min read

Why Peptide-Related Impurities Receive Regulatory Attention

Peptide impurities may differ from the intended sequence by only one residue or modification while retaining biological or immune activity.

By
Jacob Leisher, Researcher, Cendrix
Reviewed by
Jacob Doyon, Researcher, Cendrix
Published
May 3, 2026
Last reviewed
June 26, 2026

A high main-peak percentage does not answer every safety or comparability question. The identity and behavior of related impurities matter.

Synthesis creates sequence-related impurities

Stepwise synthesis can produce deletion sequences, insertions, truncations, epimers, incompletely deprotected forms, oxidized residues, adducts, and rearranged products. Some impurities have masses and chromatographic behavior close to the intended peptide.

Closely related structures can remain biologically active

A one-residue difference may reduce activity, preserve activity, shift receptor selectivity, or create an entirely different profile. The biological relevance cannot always be inferred from abundance alone.

Immunogenicity is a central concern

Aggregates, modified forms, sequence variants, and process impurities may increase immune recognition. Anti-drug antibodies can affect exposure, neutralize activity, cross-react with endogenous proteins, or contribute to hypersensitivity.

Analytical methods have different blind spots

HPLC can separate many species but may not resolve co-eluting impurities. Intact mass confirms mass but may not locate a modification. Sequence mapping and orthogonal chromatographic, spectrometric, and biological methods may be needed.

Manufacturing route affects the impurity profile

Recombinant and synthetic routes can generate different process-related impurities. Even two synthetic processes using the same nominal sequence may produce different distributions of deletion, oxidation, epimerization, or residual reagent species.

Specifications should be risk-based

Not every trace impurity requires the same level of characterization. Risk assessment considers abundance, structural relationship, biological activity, immunogenicity potential, process consistency, and exposure.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.

Cendrix analysis

purity is the beginning of impurity analysis, not the conclusion. A credible quality profile identifies what the main peak is, what else may be present, and which methods support that conclusion.

Selected primary references

  1. [1]FDA guidance on ANDAs for certain highly purified synthetic peptide products
  2. [2]FDA workshop on immunogenicity risk for generic peptide products
  3. [3]FDA PCAC meeting materials on peptide impurities

Editorial note. Written by Jacob Leisher and scientifically reviewed by Jacob Doyon. See our editorial standards, citation policy, and corrections policy.

Continue reading

Fundamentals

What Makes a Peptide Different From a Protein or Small Molecule?

Peptides occupy a distinct scientific space between traditional small molecules and larger proteins. Understanding that distinction is essential for interpreting research, evaluating material identity, and designing reproducible experiments.

Fundamentals

Why Peptide Structure Matters: Sequence, Conformation, and Biological Activity

Even a single amino-acid substitution can change receptor affinity, stability, selectivity, or degradation. Peptide structure is not a footnote, it is the foundation of the experiment.

Structure

Linear vs Cyclic Peptides: How Structure Changes Research Behavior

Cyclization can improve stability and constrain a peptide into a useful binding shape, but it also creates new design and analytical tradeoffs.